**SUPPLEMENTARY MATERIAL**

|  |  |  |
| --- | --- | --- |
| **Enterobacteriaceae** | **Pseudomonas** | **Gram-positive bacteria** |
| Ceftriaxone | Ceftazidime | Linezolid |
| Cefotaxime | Meropenem | Vancomycin |
| Meropenem | Ciprofloxacin | Clindamycin |
| Imipenem | Levofloxacin | Penicillin |
| Piperacillin-tazobactam | Piperacillin-tazobactam | Erythromycin |
| Gentamicin | Gentamicin | Gentamicin |
| Netilmicin | Amikacin | Cefoxitin |
| Amikacin | Imipenem | Oxacillin |
| Ciprofloxacin | Colistin | Tetracycline |
| Co-trimoxazole |  |  |
| Colistin |  |  |
| Tigecycline |  |  |
| Ampicillin |  |  |
| Nitrofurantoin |  |  |
| Ceftazidime |  |  |

Supplementary Table 1 : Panel of antimicrobial agents employed against various microbes

|  |  |  |  |
| --- | --- | --- | --- |
| **\*Antibiotic (isolates tested)** | **Resistant (%)** | **Sensitive (%)** | **Intermediate (%)** |
| Ceftriaxone (19) | 19 (100.0) | 0 | 0 |
| Ceftazidime (14) | 14 (100.0) | 0 | 0 |
| Cefotaxime (5) | - | - | - |
| Meropenem (20) | 19 (95.0) | 0 | 1 (5.0) |
| Imipenem (23) | 18 (78.3) | 3 (13.1) | 2 (8.7) |
| Piperacillin-Tazobactam (24) | 18 (69.2) | 3 (11.5) | 3 (11.5) |
| Gentamicin (19) | 18 (94.7) | 1 (5.3) | 0 |
| Netilmicin (13) | 12 (92.3) | 1 (7.7) | 0 |
| Amikacin (22) | 19 (86.4) | 2 (9.1) | 1 (4.5) |
| Ciprofloxacin (19) | 19 (100.0) | 0 | 0 |
| Levofloxacin (13) | 13 (100.0) | 0 | 0 |
| Colistin (26) | 1 (3.9) | 25 (96.1) | 0 |
| Tigecycline (8) | 0 | 7 (87.5) | 1 (12.5) |
| Ampicillin-sulbactam (2) | - | - | - |
| Cotrimoxazole (14) | 14 (100.0) | 0 | 0 |

Supplementary Table 2 :Susceptibility profile of Acinetobacter species (n=30)

(\*Not all organisms were tested for all antibiotics)

|  |  |  |  |
| --- | --- | --- | --- |
| **\*Antibiotic (isolates tested)** | **Resistant (%)** | **Sensitive (%)** | **Intermediate (%)** |
| Ceftriaxone (9) | 9 (100.00) | 0 | 0 |
| Ceftazidime (2) | - | - | - |
| Cefotaxime (6) | 6 (100.0) | 0 | 0 |
| Meropenem (5) | 4 (80.0) | 1 (20.0) | 0 |
| Imipenem (10) | 9 (90.0) | 1 (10.0) | 0 |
| Piperacillin-Tazobactam (11) | 6 (54.5) | 5 (45.5) | 0 |
| Gentamicin (4) | - | - | - |
| Netilmicin (1) | - | - | - |
| Amikacin (9) | 4 (44.4) | 4 (44.4) | 1 (11.1) |
| Cotrimoxazole (7) | 7 (100.0) | 0 | 0 |
| Amoxiclav (3) | - | - | - |
| Colistin (7) | 0 | 7 (100.0) | 0 |
| Ampicillin (8) | 8 (100.0) | 0 | 0 |
| Ciprofloxacin (5) | 5 (100.0) | 0 | 0 |
| Levofloxacin (8) | 8 (100.0) | 0 | 0 |
| Nitrofurantoin (8) | 5(63.5%) | 3(37.5%) | 0 |

Supplementary Table 3:Susceptibility profile of E. coli organism (n=12)

(\*Not all organisms were tested for all antibiotics)

|  |  |  |  |
| --- | --- | --- | --- |
| **\*Antibiotic (isolates tested)** | **Resistant (%)** | **Sensitive (%)** | **Intermediate (%)** |
| Ceftriaxone (17) | 17 (100.0) | 0 | 0 |
| Ceftazidime (1) | - | - | - |
| Cefotaxime (5) | - | - | - |
| Meropenem (12) | 10 (83.3) | 0 | 2 (16.7) |
| Imipenem (15) | 12 (80.0) | 1 (6.7) | 2 (13.3) |
| Piperacillin-Tazobactam (18) | 17 (94.4) | 1 (5.6) | 0 |
| Gentamicin (12) | 9 (75.0) | 3 (25.0) | 0 |
| Netilmicin (8) | 8 (100.0) | 0 | 0 |
| Amikacin (19) | 13 (68.4) | 5 (26.3) | 1 (5.3) |
| Cotrimoxazole (15) | 14 (93.3) | 1 (6.7) | 0 |
| Amoxiclav (8) | 8 (100.0) | 0 | 0 |
| Colistin (15) | 1 (6.7) | 14 (93.3) | 0 |
| Ampicillin (12) | 12 (100.0) | 0 | 0 |
| Ciprofloxacin (13) | 10 (76.9) | 2 (15.4) | 1 (7.7) |
| Levofloxacin (3) | - | - | - |

Supplementary Table 4:Susceptibility profile of Klebsiella sp.(n=19)

(\*Not all organisms were tested for all antibiotics)

Supplementary Table 5:Susceptibility profile of MSSA organism. (n=4)

(\*Not all organisms were tested for all antibiotics)

|  |  |  |  |
| --- | --- | --- | --- |
| **\*Antibiotic (isolates tested)** | **Resistant (%)** | **Sensitive (%)** | **Intermediate (%)** |
| Erythromycin (4) | 3 (75.0) | 1 (25.0) | 0 |
| Penicillin (4) | 4 (100.0) | 0 | 0 |
| Clindamycin (4) | 3 (75.0) | 1 (25.0) | 0 |
| Linezolid (2) | 1 (50.0) | 1 (50.0) | 0 |
| Vancomycin (4) | 0 | 4 (100.0) | 0 |
| Tetracycline (3) | 3(100) | 0 | 0 |
| Gentamycin (4) | 2 (50) | 2 (50.0) | 0 |
| Oxacillin (4) | 4 (100) | 0 | 0 |
| Ciprofloxacin (3) | 3 (100) | 0 | 0 |
| Cefoxitin (3) | 3(100) | 0 | 0 |

|  |  |  |  |
| --- | --- | --- | --- |
| **\*Antibiotic (isolates tested)** | **Resistant (%)** | **Sensitive (%)** | **Intermediate (%)** |
| Ceftazidime (8) | 8 (100.0) | 0 | 0 |
| Gentamycin (9) | 7 (77.8) | 1 (11.1) | 1 (11.1) |
| Piperacillin-Tazobactam (8) | 5 (62.5) | 3 (37.5) | 0 |
| Meropenem (5) | 4 (80.0) | 1 (20.0) | 0 |
| Imipenem (5) | 4 (80.0) | 1 (20.0) | 0 |
| Amikacin (6) | 2 (33.3) | 4 (66.7) | 0 |
| Ciprofloxacin (6) | 4 (66.7) | 2 (33.3) | 0 |
| Levofloxacin (3) | - | - | - |
| Colistin (6) | 0 | 6(100) | 0 |

Supplementary Table 6:Susceptibility profile of Pseudomonas sp. (n=9)

(\*Not all organisms were tested for all antibiotics)

|  |  |  |  |
| --- | --- | --- | --- |
| **\*Antibiotic (isolates tested)** | **Resistant (%)** | **Sensitive (%)** | **Intermediate (%)** |
| Erythromycin (2) | 2 (100.0) | 0 | 0 |
| Penicillin (2) | 2 (100.0) | 0 | 0 |
| Clindamycin (2) | 2 (100.0) | 0 | 0 |
| Linezolid (2) | 0 | 2 (100.0) | 0 |
| Vancomycin (2) | 0 | 1 (50.0) | 1 (50.0) |
| Gentamycin (2) | 1 (50.0) | 1 (50.0) | 0 |

Supplementary Table 7:Susceptibility profile of Enterococcus sp. (n=2)

(\*Not all organisms were tested for all antibiotics)